-
Posted: November 18th, 2019, 3:00am GMT
Conditions: Advanced Melanoma
Interventions: Drug: Combination of TIL Transfer with anti-PD-1 Therapy and low dose IL-2
Sponsors: University Hospital, Basel, Switzerland; GMP network of Basel
Completed
-
Posted: November 14th, 2019, 3:00am GMT
Conditions: Schwannomatosis; Pain
Interventions: Drug: Tanezumab; Drug: Placebo
Sponsors: Massachusetts General Hospital; Pfizer
Active, not recruiting
-
Posted: November 12th, 2019, 3:00am GMT
Conditions: Merkel Cell Carcinoma; Cutaneous Squamous Cell Carcinoma; Non-Melanoma Skin Cancers
Interventions: Biological: IFx-Hu2.0
Sponsors: TuHURA Biosciences, Inc.; H. Lee Moffitt Cancer Center and Research Institute; University of Southern California; Dana-Farber Cancer Institute; Huntsman Cancer Institute
Active, not recruiting
-
Posted: November 8th, 2019, 3:00am GMT
Conditions: Neoplasms; Melanoma
Interventions: Drug: Modakafusp Alfa; Drug: Pembrolizumab
Sponsors: Takeda
Completed
-
Posted: November 8th, 2019, 3:00am GMT
Conditions: Advanced Solid Tumors; NSCLC; Bladder Cancer; HNSCC; Renal Cancer; Melanoma; Anal Cancer; Colorectal Cancer; Cholangiocarcinoma; Gastric Cancer; Hepatocellular Carcinoma; Merkel Cell Carcinoma; Cervical Cancer
Interventions: Drug: Continue PD-1/PD-L1 Inhibitors treatment; Other: Discontinue PD-1/PD-L1-1 inhibitor
Sponsors: Jason J. Luke, MD
Recruiting
-
Posted: November 5th, 2019, 3:00am GMT
Conditions: Advanced/Metastatic Melanoma
Interventions: Biological: Gebasaxturev IV; Biological: Gebasaxturev ITu; Drug: Pembrolizumab
Sponsors: Merck Sharp & Dohme LLC
Terminated